BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Meetings conducted with Institutional Investors/Research Analysts.18-02-2023
18-02-2023
Biocon recalls 3,665 bottles of antifungal drug in US for failed degradation specifications
In its latest Enforcement Report, the US health regulator said that the Bengaluru-based firm is recalling 3,665 bottles of Posaconazole Delayed-Release Tablets (100 mg, 60-count bottle).18-02-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to the captioned subject, please find enclosed the Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). The above information will also be available on the website of the Company at https://www.biocon.com.17-02-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated February 14, 2023 with regard to the Unaudited Financial Results for the quarter and nine months ended December 31, 2022, please find enclosed copies of newspaper advertisement published in Financial Express (English Language-All India Edition) and Vijayavani (Kannada-Bengaluru Edition) on February 16, 2023. The above information is also available on the website of the Company at www.biocon.com.16-02-2023
Biocon reports a consolidated net loss of Rs 42 crore in Q3. Here's what analysts say
A one-time loss of Rs 271 crore during the quarter, mainly owing to professional fees paid for the acquisition of the global biosimilars business of American company Viatris, triggered the loss16-02-2023
BIOCON LTD. - 532523 - Reminder Letter To Holders Of Physical Securities For Furnishing Of PAN, KYC Details And Nomination
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, please note that the Company has sent reminder letter on February 14, 2023 to holders of physical securities, for furnishing of PAN, KYC details and nomination and also intimating the availability of filing arbitration with the Stock Exchanges regarding any dispute against the Company or its Registrar and Share Transfer Agent. Copy of the reminder letter is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge.15-02-2023
BIOCON LTD. - 532523 - Presentation And Video Recording Of Q3 FY23 Earnings Call
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find enclosed the presentation on Q3 FY23 Earnings Call conducted today i.e. on February 15, 2023. The same is also available on the website of the Company at www.biocon.com. Further, the Video Recording w.r.t. the Earnings Call is also available on the website of the Company at https://www.biocon.com/news-biocon/video-gallery-biocon/quarterly-statements-biocon/#1653297216088-5a4e9281-2d49. Kindly take the above said information on record.15-02-2023
Biocon Results Earnings Call for Q3FY23
Conference Call with Biocon Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: Kiran Mazumdar Shaw and Senior Team15-02-2023
Q3FY23 Quarterly Result Announced for Biocon Ltd.
Biotechnology firm Biocon announced Q3FY23 results: Q3FY23: Consolidated revenues for Q3FY23 increased 36% YoY to Rs 3,020 crore. Core EBITDA (excluding R&D; expense, licensing income, forex, dilution gain in Bicara and mark-to-market movement on investments) grew 49% to Rs 1,069 crore, representing healthy core operating margins of 36% versus 33% in the same quarter last year. Net R&D; investments for the quarter grew by 144% to Rs 337 crore, representing 16% of revenues ex-Syngene. This demonstrates Biocon’s advancing pipeline that will drive its future growth. Profit before tax and exceptional items stood at Rs 246 crore compared to Rs 269 crore during the same quarter last fiscal. This decline is due to higher interest and amortisation costs resulting from the Viatris deal. Net profit for the quarter, excluding exceptional items, stood at Rs 140 crore versus Rs 187 crore in Q3FY22. The profit was also impacted due to the dilution of Biocon’s stake in Biocon Biologics and Syngene. “Q3FY23 has been an eventful quarter which saw the completion of the global acquisition of our partnered Biosimilars business from Viatris on Nov 29, 2022. We are now implementing country-wise integration of the business to maximize the value of the combined entity to propel growth. Biosimilars as a business segment offers differentiated growth to Biocon Biologics based on vertical integration and a unique portfolio of Insulins and antibody-based immunotherapeutics. This quarter captures a fraction of the acquired business, but from Q4FY23 onwards, the financials will recognise the entire Biosimilars business. “Biocon’s consolidated revenues for the quarter grew 36% to Rs 3,020 crore on the back of robust performance across all its three businesses. The biggest contribution came from the Biosimilars business, which reported a 54% increase in revenues to Rs 1,507 crore. Research Services revenues at Rs 786 crore and Generics business revenues at Rs 718 crore, grew 23% and 18%, respectively. The advancement of our research pipeline led to Rs 337 crore Net R&D; investments this quarter, which will drive Biocon’s future growth. We reported a strong EBITDA growth of 35% to Rs 723 crore, representing a healthy EBITDA margin of 24%. Core EBITDA grew 49% to Rs 1,069 crore. As a part of our strategy to reduce the acquisition debt, Biocon has raised funds through a partial divestment of its stake in Syngene. “We expect to end FY23 on a strong note with healthy growth across businesses. Biocon Biologics is tracking towards exiting the year at a USD 1 billion trajectory, excluding vaccines.” commented - Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics. Result PDF15-02-2023
Viatris deal-related expenses drag Biocon's Q3 net into Rs 42 cr loss
This, even as revenues rise 36% and Ebitda is up 35%14-02-2023